You are here

Dupixent

3 Reasons Regeneron Stock Could Start Climbing Again

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Flag link:

Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing

Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing

Fierce Pharma

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Yahoo/Reuters

eosinophilic esophagitis

Flag link:

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Fierce Pharma

Flag link:

Sanofi indicates dupilumab could be used to treat nasal polyps

Sanofi indicates dupilumab could be used to treat nasal polyps

Yahoo/Reuters

Flag link:

5 Things Regeneron's CEO Said as the Biotech Stock Sank

5 Things Regeneron's CEO Said as the Biotech Stock Sank

Motley Fool

Leonard Schleifer

Flag link:

Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing

Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing

Xconomy

Flag link:

AbbVie preps JAK atopic dermatitis candidate for phase 3

AbbVie preps JAK atopic dermatitis candidate for phase 3

Fierce Biotech

clinical trials

atopic dermatitis

Flag link:

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Fierce Pharma

Flag link:

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Fierce Pharma

Flag link:

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Fierce Pharma

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Bizjournals.com

Flag link:

How a $37,000-a-year medicine sets a good model for drug pricing

How a $37,000-a-year medicine sets a good model for drug pricing

Stat

Flag link:

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Motley Fool

Flag link:

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Fierce Pharma

Flag link:

As blockbuster drugs fizzle, biotech looks warily to the next big thing

As blockbuster drugs fizzle, biotech looks warily to the next big thing

Stat

Flag link:

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

Yahoo/Reuters

Flag link:

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Yahoo/Reuters

Flag link:

Pages